<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-4157</journal-id>
<journal-title><![CDATA[Biomédica]]></journal-title>
<abbrev-journal-title><![CDATA[Biomédica]]></abbrev-journal-title>
<issn>0120-4157</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-41572017000500086</article-id>
<article-id pub-id-type="doi">10.7705/biomedica.v37i2.2818</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efecto del tratamiento prenatal con espiramicina en la frecuencia de retinocoroiditis por toxoplasmosis congénita en una cohorte colombiana]]></article-title>
<article-title xml:lang="en"><![CDATA[Effect of antenatal spiramycin treatment on the frequency of retinochoroiditis due to congenital toxoplasmosis in a Colombian cohort]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zuluaga]]></surname>
<given-names><![CDATA[Liliana María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[John Camilo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castaño]]></surname>
<given-names><![CDATA[Carlos Felipe]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Donado]]></surname>
<given-names><![CDATA[Jorge Hernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Pontificia Bolivariana Grupo de Investigación en Oftalmología ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Pablo Tobón Uribe Departamento de Investigación ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2017</year>
</pub-date>
<volume>37</volume>
<fpage>86</fpage>
<lpage>91</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-41572017000500086&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-41572017000500086&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-41572017000500086&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción.  La toxoplasmosis de la gestación es frecuente y grave. Hasta ahora no hay consenso sobre la utilidad del tratamiento para prevenir complicaciones oculares en el neonato. En la actualidad, uno de los medicamentos utilizados en las madres diagnosticadas es la espiramicina oral. Infortunadamente, en algunas mujeres gestantes no se hace el diagnóstico prenatal y, por esta u otras razones, no reciben el tratamiento.  Objetivo.  Describir la relación entre el tratamiento con espiramicina durante el embarazo en madres con toxoplasmosis de la gestación y la presentación de toxoplasmosis ocular en los recién nacidos.  Materiales y métodos. Se llevó a cabo un estudio observacional descriptivo de serie de casos. Se evaluó una serie prospectiva de pacientes con toxoplasmosis de la gestación durante tres años de seguimiento en el Servicio de Retinología de la Clínica Universitaria Bolivariana de Medellín.  Resultados. Se registraron 23 madres con diagnóstico de toxoplasmosis de la gestación. Quince de ellas (65 %) recibieron durante la gestación tratamiento con espiramicina en dosis de 3 g al día; uno de los neonatos (6,6 %) presentó toxoplasmosis ocular. De las ocho (35 %) pacientes que no recibieron tratamiento, cinco (62,5 %) tuvieron hijos con compromiso ocular por toxoplasma. La razón de momios (odds ratio, OR) del efecto protector contra dicho compromiso en los pacientes cuyas madres recibieron tratamiento fue de 0,04 (IC95% 0,00-0,67), con valor de p menor de 0,01 en la prueba exacta de Fisher. Solo se evidenció compromiso del sistema nervioso central por toxoplasmosis mediante las imágenes de tomografía o ecografía cerebral en dos (14 %) pacientes de las 14 en quienes se hicieron estos estudios. Los dos pacientes presentaron, además, compromiso ocular; ambos fueron diagnosticados en el momento del nacimiento y sus madres no habían recibido tratamiento prenatal.  Conclusiones. Estos resultados evidencian que el tratamiento con espiramicina durante el embarazo en la toxoplasmosis de la gestación redujo en 96 % (IC95% 33-100 %) el riesgo relativo de presentar la enfermedad en el recién nacido.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstrat  Introduction: Gestational toxoplasmosis is frequent and severe. There is still debate about the benefits of treatment against ocular manifestations in the newborn. Spiramycin treatment is used for this purpose, unfortunately prenatal diagnosis is sometimes delayed and pregnant women are not treated.  Objective: To describe the relationship between treatment with spiramycin during pregnancy in mothers with gestational toxoplasmosis and development of ocular toxoplasmosis in newborns.  Materials and methods: We conducted a descriptive study of a case series. We evaluated a prospective cohort of patients diagnosed with gestational toxoplasmosis during three years at the Retinology Service at the Clínica Universitaria Bolivariana in Medellín.  Results: Gestational toxoplasmosis was found in 23 mothers; 15 (65%) were treated during pregnancy with 3 g per day of spiramycin, eight (35%) patients were untreated. In the treated group just one newborn developed ocular toxoplasmosis (6.6%), in contrast with five (62.5%) of the eight patients who did not receive treatment. These results suggest that pregnancy treatment reduces the relative risk of ocular toxoplasmosis in the newborn by 96% (95% CI: 33 - 100%). Only two (14%) of the patients who were evaluated, had nervous system involvement related to toxoplasmosis in CT scan or cerebral ultrasound. These two patients also developed ocular pathology and were diagnosed at the time of birth, so they did not received antenatal treatment.  Conclusions: A protective effect was found against the ocular involvement in patients whose mother received treatment with spiramycin (OR=0.04;95% CI: 0.00-0.67), p&lt;0.01 (Fisher&#8217;s Exact Test).]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[toxoplasmosis ocular]]></kwd>
<kwd lng="es"><![CDATA[toxoplasmosis congénita]]></kwd>
<kwd lng="es"><![CDATA[embarazo]]></kwd>
<kwd lng="es"><![CDATA[terapéutica]]></kwd>
<kwd lng="es"><![CDATA[espiramicina]]></kwd>
<kwd lng="en"><![CDATA[Toxoplasmosis, ocular]]></kwd>
<kwd lng="en"><![CDATA[toxoplasmosis, congenital]]></kwd>
<kwd lng="en"><![CDATA[pregnancy]]></kwd>
<kwd lng="en"><![CDATA[therapeutics]]></kwd>
<kwd lng="en"><![CDATA[spiramycin]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The Spanish Society of Pediatric Infectious Diseases Guidelines for the diagnosis and treatment of congenital toxoplasmosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baquero-Artigao]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[del Castillo-Martín]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fuentes-Corripio]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Goncé-Mellgren]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fortuny-Guasch]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[de la Calle Fernández-Miranda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[An Pediatr (Barc)]]></source>
<year>2013</year>
<volume>79</volume>
<page-range>116.e1-116.e16</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Screening by ophthalmoscopy for Toxoplasma retinochoroiditis in Colombia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[De la Torre]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz-Ramírez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Marín]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>2007</year>
<volume>143</volume>
<page-range>354-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Ocular toxoplasmosis in the developing world]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arévalo]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Belfort Jr]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Muccioli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Espinoza]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
</person-group>
<source><![CDATA[Int Oph-thalmol Clin]]></source>
<year>2010</year>
<volume>50</volume>
<page-range>57-69</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antibióticos sistémicos para retinocoroiditis por toxoplasmosis Revisión sistemática de la literatura]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Donado]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[De La Cruz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Montoya]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Medicina UPB]]></source>
<year>2012</year>
<volume>31</volume>
<page-range>170-80</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Management of Toxoplasma gondii infection during pregnancy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montoya]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Remington]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2008</year>
<volume>47</volume>
<page-range>554-66</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Congenital toxoplasmosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kieffer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Wallon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Handb Clin Neurol]]></source>
<year>2013</year>
<volume>112</volume>
<page-range>1099-101</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Evaluación del tratamiento de la toxoplasmosis gestacional en una cohorte colombiana]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Marín]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[Infectio]]></source>
<year>2005</year>
<volume>9</volume>
<page-range>16-23</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Congenital toxoplasmosis and prenatal care state programs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Avelino]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Amaral]]></surname>
<given-names><![CDATA[WN]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Rassi]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Gomes]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
</person-group>
<source><![CDATA[BMC Infect Dis]]></source>
<year>2014</year>
<volume>18</volume>
<page-range>14-33</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Ophthalmic outcomes of congenital toxoplasmosis followed until adolescence]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wallon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Garweg]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Abrahamowicz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cornu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vinault]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Quantin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatrics]]></source>
<year>2014</year>
<volume>133</volume>
<page-range>e601-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Long-term ocular outcome in congenital toxoplasmosis: A prospective cohort of treated children]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faucher]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[García-Meric]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Franck]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Minodier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Francois]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gonnet]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[J Infect]]></source>
<year>2012</year>
<volume>64</volume>
<page-range>104-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epidemiology, pathophysiology, and the future of ocular toxoplasmosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kijlstra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Petersen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Ocul Immunol Inflamm]]></source>
<year>2014</year>
<volume>22</volume>
<page-range>138-47</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epidemiology of ocular toxoplasmosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petersen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kijlstra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Stanford]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Ocul Immunol Inflamm]]></source>
<year>2012</year>
<volume>20</volume>
<page-range>68-75</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Ocular toxoplasmosis: A global reassessment. Part I: Epidemiology and course of disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holland]]></surname>
<given-names><![CDATA[GN]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>2003</year>
<volume>136</volume>
<page-range>973-88</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Acquired toxoplasmic infection as the cause of toxoplasmic retinochoroiditis in families]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silveira]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Belfort]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Burnier]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nussenblatt]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>1988</year>
<volume>106</volume>
<page-range>362-4</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[First Colombian multicentric newborn screening for congenital toxoplasmosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Marín]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[De la Torre]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[ángel-Muller]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rubio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Arenas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Osorio]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS Negl Trop Dis]]></source>
<year>2011</year>
<volume>5</volume>
<page-range>e1195</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevalence of infection with Toxoplasma gondii among pregnant women in Cali, Colombia, South America]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosso]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Les]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Agudelo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Villalobos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chaves]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Tunubala]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Trop Med Hyg]]></source>
<year>2008</year>
<volume>78</volume>
<page-range>504-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A newborn screening programme for congenital toxoplasmosis in the setting of a country with less income]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Marín]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Montoya]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Giraldo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Castaño]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Dis Child]]></source>
<year>2007</year>
<volume>92</volume>
<page-range>88</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Métodos tradicionales y moleculares en el diagnóstico de la toxoplasmosis y su aplicación en el contexto clínico]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aristizábal]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
</person-group>
<source><![CDATA[Medicina UPB]]></source>
<year>2013</year>
<volume>32</volume>
<page-range>54-67</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Newborn screening for congenital toxoplasmosis: Feasible, but benefits are not established]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gilbert]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dezateux]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Dis Child]]></source>
<year>2006</year>
<volume>91</volume>
<page-range>629-31</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Assessment of laboratory methods used in the diagnosis of congenital toxoplasmosis after maternal treatment with spiramycin in pregnancy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Avelar]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Amaral]]></surname>
<given-names><![CDATA[WN]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Avelino]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<source><![CDATA[BMC Infect Dis]]></source>
<year>2014</year>
<volume>14</volume>
<page-range>349</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Toxoplasmosis in pregnancy: Prevention, screening, and treatment]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paquet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Yudin]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<source><![CDATA[J Obstet Gynaecol Can]]></source>
<year>2013</year>
<volume>35</volume>
<page-range>78-81</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevention of mother-to-child transmission of toxoplasmosis: Perspectives]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mandelbrot]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Gynecol Obstet Fertil]]></source>
<year>2012</year>
<volume>40</volume>
<page-range>591-8</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Congenital toxoplasmosis treatment]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serranti]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Buonsenso]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Valentini]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Rev Med Pharmacol Sci]]></source>
<year>2011</year>
<volume>15</volume>
<page-range>193-8</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Positive benefit of post-natal treatment in congenital toxoplasmosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Marín]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[De laTorre]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Dis Child]]></source>
<year>2007</year>
<volume>92</volume>
<page-range>88-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: An observational prospective cohort study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cortina-Borja]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Wallon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Paul]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Prusa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Buffolano]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS Med]]></source>
<year>2010</year>
<volume>7</volume>
</nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valentini]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Annunziata]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Angelone]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Masini]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[De Santis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Testa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Clin Microbiol Infect Dis]]></source>
<year>2009</year>
<volume>28</volume>
<page-range>297-300</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guía de atención integral para la prevención, detección temprana y tratamiento de las complicaciones del embarazo, parto y puerperio: sección toxoplasmosis en el embarazo]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cortés]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[PI]]></given-names>
</name>
<name>
<surname><![CDATA[Arévalo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Arévalo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<source><![CDATA[Infectio]]></source>
<year>2012</year>
<volume>16</volume>
<page-range>230-46</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guía de práctica clínica para toxoplasmosis durante el embarazo y toxoplasmosis congénita en Colombia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Beltrán]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cortés]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Montoya]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Infectio]]></source>
<year>2007</year>
<volume>11</volume>
<page-range>129-41</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effectiveness of prenatal treatment for congenital toxoplasmosis: A meta-analysis of individual patients' data]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thiébaut]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Leproust]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chêne]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gilbert]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<collab>SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group</collab>
<source><![CDATA[Lancet]]></source>
<year>2007</year>
<volume>369</volume>
<page-range>115-22</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
